Lipokel is a self adjuvanting small molecule suitable for the formulation of recombinant protein vaccines. Lipokel is very effective at stimulating TLR2 receptors and can be formulated for nasal delivery of vaccines in powder form.
This was recently described in Tyne AS, Chan J, Shanahan E, Atmosukarto I, Chan H-K , Britton WJ, West NP 2013, ‘TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines.’, Vaccine, vol. 31, no. 40, pp. 4322-4329.
Like Lipovaxin the platform exploits the his-tag of a recombinant antigen for the formation of a self-adjuvanting vaccine formulation.